Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that we have downed yet another cup of stimulation. For those who care, our flavor today has traces of Tennessee whiskey, and it already comes this way, believe it or not. In any event, feel free to join us or grab a bottle of whiskey-free water, if you prefer. Meanwhile, here are some items of interest. Have a lovely day and do keep in touch …

India’s health ministry recommended waiving clinical trials for critical drugs to treat such diseases as HIV, hepatitis, and tuberculosis if the medicines have already been approved in markets such as the U.S., Japan, the European Union, Canada, and Australia at least two years ago, the Economic Times informs us. However, some doctors tell PharmaBiz they have concerns about this policy.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy